非肥胖型与肥胖型非酒精性脂肪性肝病患者代谢特征和肝脂肪变程度比较*

doi:10.3969/j.issn.1672-5069.2022.05.016

摘要/Abstract

摘要： 目的比较非肥胖型与肥胖型非酒精性脂肪性肝病(NAFLD)患者代谢特征和肝脂肪变程度差异。方法 2015年1月～2021年6月我院诊治NAFLD患者274例,根据体质指数(BMI)=25 kg/m²,将其分为非肥胖型66例和肥胖型208例。计算胰岛素抵抗指数(HOMA-IR),行磁共振仪检查,应用仪器自带软件计算肝脏脂肪含量(LFC)和腹部皮下脂肪厚度(ASFT),使用FibroTouch测量肝脏受控衰减参数(CAP),使用多普勒超声诊断仪检测颈动脉内膜中层厚度(CIMT),将肝脂肪变分为Ⅰ级、Ⅱ级和Ⅲ级。结果非肥胖型NAFLD患者BMI为(23.4±1.4)kg/m²、血清丙氨酸氨基转移酶水平为24.2(19.6,35.8)U/L,天冬氨酸氨基转移水平为25.0(18.7,32.3)U/L,甘油三酯为(1.9±0.4)mmol/L,高密度脂蛋白为(1.3±0.4)mmol/L,空腹血糖为(5.0±0.7)mmol/L,空腹胰岛素为7.0(4.8,9.4)μU/mL,HOMA-IR为1.6(1.1,2.3),尿酸为376.5(294.3,430.5)μmol/L,与肥胖型组【分别为(28.6±3.0)kg/m²、88.4(55.4,160.5)U/L、71.5(64.4,141.6)U/L、(2.8±0.6)mmol/L、(1.1±0.3)mmol/L、(5.8±0.8)mmol/L、10.4(7.7,14.2)μU/mL、2.5(1.8,3.4)和442.3(346.4,484.5)μmol/L】比,差异显著(P<0.05); LFC为8.2(6.2,13.4)%,ASFT 为(19.2±5.7)mm,CAP为(233.2±40.5)dB/m和CIMT为0.6(0.6,0.7)mm,与肥胖型组【分别为14.6(10.0,18.6)%、(24.6±8.2) mm、(284.6±46.0) dB/m和0.8(0.6,0.9)mm】比,差异显著(P<0.05);Ⅰ级肝脂肪变发生率为43.9%,显著高于肥胖型组的26.0%,而Ⅲ级肝脂肪变发生率为22.7%,显著低于肥胖型组的40.4%(P<0.05)。结论与肥胖型NAFLD患者比,非肥胖型患者代谢紊乱程度和肝脂肪变程度显著较轻。因此,在临床实践中如何加强对这部分患者的监管仍需要进一步研究。

关键词: 非酒精性脂肪性肝病, 肝脂肪变, 肝脂肪含量, 腹部皮下脂肪厚度, 肝脏受控衰减参数, 颈动脉内膜中层厚度, 非肥胖人群

Abstract: Objective The purpose of this study was to compare the metabolic characteristics and liver steatosis in non-obese and obese patients with nonalcoholic fatty liver diseases (NAFLD). Methods 274 patients with NAFLD were recruited in our hospital between January 2015 and June 2021, and were divided into non-obese (n=66) and obese (n=208) groups based on basic mass index equal to 25 kg/m². The liver fat content (LFC) and abdominal subcutaneous fat thickness (ASFT) were obtained by MR scan. The controlled attenuation parameter (CAP) was detected by FibroTouch check-up and the carotid intima-media thickness (CIMT) was assessed by ultrasonography. Results In patients with non-obese NAFLD, the BMI was (23.4±1.4)kg/m², serum alanine aminotransferase level was 24.2(19.6,35.8)U/L, aspartate aminotransferase level was 25.0(18.7, 32.3)U/L, triglyceride level was (1.9±0.4)mmol/L, high-density lipoprotein cholesterol level was (1.3±0.4)mmol/L, fasting blood glucose level was (5.0±0.7)mmol/L, fasting insulin level was 7.0(4.8, 9.4)μU/mL, the HOMA-IR was 1.6(1.1, 2.3) and uric acid level was 376.5(294.3, 430.5)μmol/L, significantly different as compared to [(28.6±3.0)kg/m², 88.4(55.4, 160.5)U/L, 71.5(64.4, 141.6)U/L, (2.8±0.6)mmol/L, (1.1±0.3)mmol/L, (5.8±0.8)mmol/L, 10.4(7.7, 14.2)μU/mL, 2.5(1.8, 3.4) and 442.3(346.4, 484.5)μmol/L, respectively, P<0.05] in obese patients; the LFC was 8.2(6.2, 13.4)%, the ASFT was 为(19.2±5.7)mm, the CAP was (233.2±40.5)dB/m and the CIMT was 0.6(0.6, 0.7)mm, significantly different compared to [14.6(10.0, 18.6)%, (24.6±8.2) mm, (284.6±46.0) dB/m and 0.8(0.6, 0.9)mm, respectively, P<0.05] in obese patients; the incidence of liver steatosis grade Ⅰ was 43.9%, significantly higher than 26.0%, while the incidence of liver steatosis grade Ⅲ was 22.7%, significantly lower than 40.4%(P<0.05) in obese patients. Conclusion The metabolic disorders and liver steatosis in non-obese patients with NAFLD are mild, and how to monitor them is really a challenge in clinical practice.

Key words: Nonalcoholic fatty liver disease, Liver steatosis, Liver fat content, Abdominal subcutaneous fat thickness, Controlled attenuation parameter, Carotid intima-media thickness, Non-obese

王慧, 汤展, 常文娟, 芦超. 非肥胖型与肥胖型非酒精性脂肪性肝病患者代谢特征和肝脂肪变程度比较^*[J]. 实用肝脏病杂志, 2022, 25(5): 669-672.

Wang Hui, Tang Zhan, Chang Wenjuan, et al.. Comparison of metabolic characteristics and liver steatosis in non-obese and obese patients with nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2022, 25(5): 669-672.

参考文献

[1]Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut, 2016, 65(8):1359-1368.
[2]Zou Y, Yu M, Sheng G. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a non-obese Chinese population with normal blood lipid levels: a prospective cohort study. Lipids Health Dis, 2020, 19(1):145.
[3]Chen ZY, Liu M, Jing LP, et al. Erythrocyte membrane n-3 polyunsaturated fatty acids are inversely associated with the presence and progression of nonalcoholic fatty liver disease in Chinese adults: a prospective study. Eur J Nutr, 2020, 59(3):941-951.
[4]Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol, 2020, 5(4):362-373.
[5]Qin S, Wang J, Zhou C, et al. The association between a non-invasive hepatic fibrosis score and urolithiasis among non-alcoholic fatty liver disease (NAFLD) patients in China: a cross-sectional study. BMJ Open, 2019, 9(8):e027702.
[6]Naderian M, Kolahdoozan S, Sharifi AS, et al. Assessment of lean patients with non-alcoholic fatty liver disease in a middle income country; prevalence and its association with metabolic disorders: a cross-sectional study. ArchIran Med, 2017, 20(4):211-217.
[7]Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2020, 5(8):739-752.
[8]Kim SH, Park HY, Lee HS, et al. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity. Sci Rep, 2020, 10(1):1025.
[9]Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut, 2021[ahead of print].
[10] Kumar R, Rastogi A, Sharma MK, et al. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J Endocrinol Metab, 2013, 17(4):665-671.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2):177-186.
[12] Liu J, Wang T, He K, et al. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation. Eur Rev Med Pharmacol Sci, 2019,23(18):8158-8167.
[13] Nishioji K, Mochizuki N, Kobayashi M, et al. The impact of PNPLA3 rs738409 genetic polymorphism and weight gain≥10 kg after age 20 on non-alcoholic fatty liver disease in non-obese Japanese individuals. PLoS One, 2015, 10(10):e0140427.
[14] Gonzalez-Cantero J, Martin-Rodriguez JL, Gonzalez-Cantero A, et al. Insulin resistance in lean and overweight non-diabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI. PLoS One, 2018, 13(2):e0192663.
[15] Li C, Guo P, Okekunle AP, et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol, 2019, 34(1):256-262.
[16] Niriella MA, Kasturiratne A, Pathmeswaran A, et al. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hepatol Int, 2019, 13(3):314-322.
[17] Guo F, Zhou T, Tang J, et al. Related risk factors between subclinical carotid atherosclerosis and diabetic retinopathy in newly diagnosed type 2 diabetes mellitus in China. Exp Clin Endocrinol Diabetes, 2021, 129(4):283-288.
[18] Yang CW, Guo YC, Li CI, et al. Subclinical atherosclerosis markers of carotid intima-media thickness, carotid plaques, carotid stenosis, and mortality in community-dwelling adults. Int J Environ Res Public Health, 2020, 17(13):4745.
[19] Shin J, Lee HY, Chung WJ, et al. The association of smoothness index of central blood pressure with ambulatory carotid femoral pulse wave velocity after 20-week treatment with losartan in combination with amlodipine versus hydrochlorothiazide. J Hypertens, 2019, 37(12):2490-2497.
[20] Lin H, Ding Y, Ning C, et al. Age-specific associations between HIV infection and carotid artery intima-media thickness in China: a cross-sectional evaluation ofbaseline data from the CHART cohort. Lancet HIV, 2019, 6(12):e860-e868.

非肥胖型与肥胖型非酒精性脂肪性肝病患者代谢特征和肝脂肪变程度比较^*

Comparison of metabolic characteristics and liver steatosis in non-obese and obese patients with nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曾婷, 雷向阳, 白晓苏. 氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 624-627.
[2]	刘彦彤, 姚杨, 卢博. 荷叶调脂疏肝汤对非酒精性脂肪性肝病患者脂代谢的影响研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 657-660.
[3]	奚佳颖, 汤佳美, 刘玲玉, 王韦. 超声三维斑点追踪技术评价非酒精性脂肪性肝病合并2型糖尿病患者左心功能研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 661-664.
[4]	潘飞, 寿涓, 张冬青. 不同他汀类药物治疗非酒精性脂肪性肝病合并高脂血症患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 665-668.
[5]	陈梦绮, 范建高. 美国非酒精性脂肪性肝病诊断与治疗临床实践指南简介^*[J]. 实用肝脏病杂志, 2022, 25(5): 762-S16.
[6]	王晴, 张利莉. 当2型糖尿病遇上非酒精性脂肪性肝病:1+1＞2 ？[J]. 实用肝脏病杂志, 2022, 25(4): 460-463.
[7]	汪晓燕, 钟雪玉, 吴春燕. 沙格列汀干预非酒精性脂肪性肝病合并2型糖尿病大鼠肝组织AMPK/mTOR-TFEB自噬信号通路蛋白表达变化^*[J]. 实用肝脏病杂志, 2022, 25(4): 476-479.
[8]	张文彦, 刘芳, 刘梦露, 陈德喜, 张晶, 时红波, 于海滨. 非酒精性脂肪性肝病患者血浆外泌体差异蛋白分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 521-525.
[9]	李亚文, 周军. 化痰祛湿疏肝方联合辛伐他汀治疗非酒精性脂肪性肝病痰湿内阻证患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 526-529.
[10]	年福临, 鲁晓岚. 糖尿病与非酒精性脂肪性肝病^*[J]. 实用肝脏病杂志, 2022, 25(3): 314-317.
[11]	王诗淞, 林辉雄, 张泰胜, 董俪雯, 王英霞, 林秋香. 二甲双胍联合达格列净治疗T2DM合并NAFLD患者疗效及血清二肽基肽酶4和C肽变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 379-382.
[12]	蔡冬梅, 吴文娟, 姜亦伦, 居敏昊. CT检测非酒精性脂肪性肝病合并高危冠状动脉斑块患者冠状动脉指标临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 383-386.
[13]	周平, 姚登福, 姚敏. NAFLD与肝细胞恶性转化相关研究新进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 157-160.
[14]	侯文靖, 吴广明, 盖慧慧. 三七总皂苷对非酒精性脂肪性肝病小鼠肝组织脂质沉积及NO/iNOS/NF-κB通路的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 174-178.
[15]	陈凯, 居峰. 多烯磷脂酰胆碱联合扶正化瘀片治疗非酒精性脂肪性肝病患者肝脏超声脂肪变性评分变化^*[J]. 实用肝脏病杂志, 2022, 25(2): 219-222.